ELIQUIS Receives FDA Approval in Reducing Certain Risks in Nonvalvular Atrial Fibrillation
Go back to ELIQUIS Receives FDA Approval in Reducing Certain Risks in Nonvalvular Atrial Fibrillation| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 56.95 -2.39 (4.03%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $59.34 | 52 Week High | $77.12 | |||
| Open | $59.00 | 52 Week Low | $49.03 | |||
| Day High | $59.14 | P/E | 36.98 | |||
| Day Low | $56.78 | EPS | $1.54 | |||
| Volume | 13,562,090 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 24.25 -0.23 (0.94%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $24.48 | 52 Week High | $37.39 | |||
| Open | $24.37 | 52 Week Low | $28.25 | |||
| Day High | $24.43 | P/E | 14.70 | |||
| Day Low | $24.14 | EPS | $1.65 | |||
| Volume | 40,677,802 | |||||
